FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

This study is looking at different treatments for advanced hepatocellular carcinoma (HCC), a type of liver cancer. Researchers want to see if adding a drug called toripalimab to a combination of other treatments will help patients live longer. One group will get FOLFOX-HAIC (a type of chemotherapy) plus lenvatinib (a cancer medicine) and toripalimab (a medicine that helps the immune system fight cancer). The other group will get FOLFOX-HAIC and lenvatinib only. Both groups will get their treatments through an artery in the liver.

To join, you must have HCC that cannot be removed by surgery and no prior treatment for it. You should not have serious liver issues like cirrhosis or other health problems such as HIV or heart issues.

• This study involves getting treatments through a liver artery.
• You cannot participate if you have severe liver problems or history of certain health issues.
• The study is double-blind, meaning neither you nor the doctors will know which treatment you receive.